PolyMedix, Inc. (OTC:PYMX) published the study of the properties of their anti-inflammatory defensin-mimetics compounds, giving a new boost to the company’s stock value.The tests made during the pre-clinical research studies were published in the December issue of Molecular Oral Microbiology. Results were satisfying, as the compounds exhibited anti-inflammatory and antimicrobial effects when tested on microbial biofilms that cause oral cavity infections.
The OTC listed company currently holds enough cash to operate for around 1.5 year, considering the average historical expenses. As the development stage company gets closer to Stage 1 trials for defensin-mimetic, the value of the venture rises as well. The current $85 million market cap might be the limit at the moment though, but short surges above the $1 per share on the market still remain a profit making possibility for short-term traders.[BANNER]
PolyMedix has recently entered Phase 2 Clinical trials for one of their antibiotic drugs. The trial on the substance called PMX-30063 was initiated on September 28, 2010, which along with some less important announcements helped the stock sustain its value.
The stock price recently broke through the most recent resistance level at $0.95 and is now testing the grounds around $1 per share. If the price would confidently move up past this level, traders could probably see a formation of sustained short-term uptrend before the excitement wears off.
